335 related articles for article (PubMed ID: 16318952)
1. Methylone and mCPP, two new drugs of abuse?
Bossong MG; Van Dijk JP; Niesink RJ
Addict Biol; 2005 Dec; 10(4):321-3. PubMed ID: 16318952
[TBL] [Abstract][Full Text] [Related]
2. mCPP: an undesired addition to the ecstasy market.
Bossong MG; Brunt TM; Van Dijk JP; Rigter SM; Hoek J; Goldschmidt HM; Niesink RJ
J Psychopharmacol; 2010 Sep; 24(9):1395-401. PubMed ID: 19304863
[TBL] [Abstract][Full Text] [Related]
3. Content of ecstasy in the Netherlands: 1993-2008.
Vogels N; Brunt TM; Rigter S; van Dijk P; Vervaeke H; Niesink RJ
Addiction; 2009 Dec; 104(12):2057-66. PubMed ID: 19804461
[TBL] [Abstract][Full Text] [Related]
4. Methamphetamine, amphetamine, MDMA ('ecstasy'), MDA and mCPP modulate electrical and cholinergic input in PC12 cells.
Hondebrink L; Meulenbelt J; Rietjens SJ; Meijer M; Westerink RH
Neurotoxicology; 2012 Mar; 33(2):255-60. PubMed ID: 21996653
[TBL] [Abstract][Full Text] [Related]
5. Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among d-amphetamine, meta-chlorophenylpiperazine and placebo.
Johanson CE; Kilbey M; Gatchalian K; Tancer M
Drug Alcohol Depend; 2006 Jan; 81(1):27-36. PubMed ID: 15975736
[TBL] [Abstract][Full Text] [Related]
6. Instability of the ecstasy market and a new kid on the block: mephedrone.
Brunt TM; Poortman A; Niesink RJ; van den Brink W
J Psychopharmacol; 2011 Nov; 25(11):1543-7. PubMed ID: 20826554
[TBL] [Abstract][Full Text] [Related]
7. [Metachlorophenylpiperazine (mCPP): a new designer drug].
Lecompte Y; Evrard I; Arditti J
Therapie; 2006; 61(6):523-30. PubMed ID: 17348609
[TBL] [Abstract][Full Text] [Related]
8. [Entactogenic drugs "ecstasy" (MDMA), "eve" (MDE) and other ring-substituted methamphetamine derivatives. A new class of substances among illegal designer drugs?].
Tretter F
Nervenarzt; 1997 Nov; 68(11):922-3. PubMed ID: 9732739
[No Abstract] [Full Text] [Related]
9. [Ecstasy, a new designer drug in the techno-scene].
Kuhlmann T
Psychiatr Prax; 1996 Nov; 23(6):266-9. PubMed ID: 9036394
[TBL] [Abstract][Full Text] [Related]
10. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
[TBL] [Abstract][Full Text] [Related]
11. Head shop compound abuse amongst attendees of the Drug Treatment Centre Board.
McNamara S; Stokes S; Coleman N
Ir Med J; 2010 May; 103(5):134, 136-7. PubMed ID: 20666082
[TBL] [Abstract][Full Text] [Related]
12. Piperazine compounds as drugs of abuse.
Arbo MD; Bastos ML; Carmo HF
Drug Alcohol Depend; 2012 May; 122(3):174-85. PubMed ID: 22071119
[TBL] [Abstract][Full Text] [Related]
13. Methylenedioxymethamphetamine (ecstasy)-related hyperthermia.
Patel MM; Belson MG; Longwater AB; Olson KR; Miller MA
J Emerg Med; 2005 Nov; 29(4):451-4. PubMed ID: 16243206
[TBL] [Abstract][Full Text] [Related]
14. The designer drug situation in Ibiza.
Lora-Tamayo C; Tena T; Rodríguez A; Moreno D; Sancho JR; Enseñat P; Muela F
Forensic Sci Int; 2004 Mar; 140(2-3):195-206. PubMed ID: 15036441
[TBL] [Abstract][Full Text] [Related]
15. GHB and synthetic cathinones: clinical effects and potential consequences.
Karila L; Reynaud M
Drug Test Anal; 2011 Sep; 3(9):552-9. PubMed ID: 21960540
[TBL] [Abstract][Full Text] [Related]
16. Reinforcing subjective effects of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") may be separable from its neurotoxic actions: clinical evidence.
McCann UD; Ricaurte GA
J Clin Psychopharmacol; 1993 Jun; 13(3):214-7. PubMed ID: 8102623
[TBL] [Abstract][Full Text] [Related]
17. Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems.
Luethi D; Kolaczynska KE; Walter M; Suzuki M; Rice KC; Blough BE; Hoener MC; Baumann MH; Liechti ME
J Psychopharmacol; 2019 Jul; 33(7):831-841. PubMed ID: 31038382
[TBL] [Abstract][Full Text] [Related]
18. Sudden cardiac death associated with methylone use.
Carbone PN; Carbone DL; Carstairs SD; Luzi SA
Am J Forensic Med Pathol; 2013 Mar; 34(1):26-8. PubMed ID: 23403480
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of new psychoactive substances: A retrospective study in hair.
Rust KY; Baumgartner MR; Dally AM; Kraemer T
Drug Test Anal; 2012 Jun; 4(6):402-8. PubMed ID: 22522922
[TBL] [Abstract][Full Text] [Related]
20. Additive inhibition of human α1β2γ2 GABAA receptors by mixtures of commonly used drugs of abuse.
Hondebrink L; Tan S; Hermans E; van Kleef RG; Meulenbelt J; Westerink RH
Neurotoxicology; 2013 Mar; 35():23-9. PubMed ID: 23266428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
